Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(16):1199; doi:10.1093/jnci/96.16.1199
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Articles by Travis, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zielinski, S. L.
Right arrow Articles by Travis, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

In Brief

Sarah L. Zielinski, Kate Travis

The first 10% of the full text of this article appears below.

FDA Announces New Office of Oncology Drug Products

The U.S. Food and Drug Administration announced in mid-July the creation of a new Office of Oncology Drug Products, which is intended to "make the review process for cancer drugs stronger and more efficient," said Health and Human Services Secretary Tommy Thompson.

The office will result from changes in the organizational structure at the FDA . . . [Full Text of this Article]

Study Estimates Number of Deaths Prevented by Cervical Cancer Screening in England and Wales

Cetuximab for Advanced Colorectal Cancer Gives Months, but Cost High


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?